MONEY

23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 15, 2024 - 16:00
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
Read More

Tags:

Previous Article

MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study...

Next Article

Air Canada reaches last-minute deal with pilots union, averting strike

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Cantor Fitzgerald maintains Neutral rating on Alphabet shares

Cantor Fitzgerald maintains Neutral rating on Alphabet ...

Tomas Kauer - Mode... Oct 9, 2024

Hamas waits for Israeli response to Gaza ceasefire proposal

Hamas waits for Israeli response to Gaza ceasefire prop...

Tomas Kauer - Mode... Jul 8, 2024

Japan August inflation seen accelerating, boosting case for BOJ rate hike - Reuters poll

Japan August inflation seen accelerating, boosting case...

Tomas Kauer - Mode... Sep 13, 2024